D-0116-2026 Class II Ongoing
FDA drug recall D-0116-2026 was initiated by ProRx LLC on Oct 15, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 8,310 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 5, 2025
- Initiation Date
- Oct 15, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 8,310 vials
Product description
Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
TX and UT
Code information
Lot Prorx051425-2, Lot Prorx051425-3 and Lot Prorx051425-4
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0116-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026